Strategic Investments in

Plant-Based Medical Products

In Kalamata, Greece, on the same latitude as central California, Kalacan has been issued one of Europe's first federal licenses to cultivate and produce medical cannabis products, for sale domestically and within other European markets.

Kalacan will initially license and develop one million square feet (25 acres), on which cultivation will be done in high-tech greenhouses while production and manufacturing will occur within EU Good Manufacturing Practice (GMP) certified facilities.

Learn More
Licensed Producer in Europe

Kalacan has a been issued a licensed to produce and commercialize medical cannabis in Europe. The license, issued by the Greek government, permits Kalacan Hellas (the Greek operating subsidiary of Kalacan) to establish industrial-scale cultivation, processing, manufacturing and distribution facilities at its site in Kalamata.

Expansion Plans

Greece is leading the way in Europe, which is anticipated to surpass the US as the world's largest plant-based pharmaceutical market in the near future, with many EU member countries already providing access to plant-based pharmaceuticals for qualified patients.

Subscribe to our Newsletter

We'll keep you up to date on major milestones and company news.

Just the occasional email, no spam.


Looking for more details about Kalacan? Complete the form below to submit a general inquiry, or to request a Kalacan Investment Presentation.

  • This field is for validation purposes and should be left unchanged.